ESSA Pharma (EPIX) Competitors

ESSA Pharma (NASDAQ:EPIX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Which has more volatility and risk, EPIX or RNAC?

ESSA Pharma has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Does the MarketBeat Community prefer EPIX or RNAC?

ESSA Pharma received 311 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 95.00% of users gave Cartesian Therapeutics an outperform vote while only 75.87% of users gave ESSA Pharma an outperform vote.

Company	Underperform	Outperform
ESSA Pharma	Outperform Votes 349 75.87%	Underperform Votes 111 24.13%
Cartesian Therapeutics	Outperform Votes 38 95.00%	Underperform Votes 2 5.00%

Is EPIX or RNAC more profitable?

ESSA Pharma has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat ESSA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ESSA Pharma	N/A	-24.61%	-23.87%
Cartesian Therapeutics	-510.72%	N/A	-6.03%

Do analysts rate EPIX or RNAC?

ESSA Pharma presently has a consensus target price of $9.50, suggesting a potential upside of 436.72%. Cartesian Therapeutics has a consensus target price of $42.67, suggesting a potential upside of 247.73%. Given ESSA Pharma's higher probable upside, equities research analysts plainly believe ESSA Pharma is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ESSA Pharma	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cartesian Therapeutics	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the media refer more to EPIX or RNAC?

In the previous week, Cartesian Therapeutics had 4 more articles in the media than ESSA Pharma. MarketBeat recorded 5 mentions for Cartesian Therapeutics and 1 mentions for ESSA Pharma. ESSA Pharma's average media sentiment score of 1.87 beat Cartesian Therapeutics' score of 0.98 indicating that ESSA Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
ESSA Pharma	Very Positive
Cartesian Therapeutics	Positive

Which has stronger valuation and earnings, EPIX or RNAC?

ESSA Pharma has higher earnings, but lower revenue than Cartesian Therapeutics. ESSA Pharma is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ESSA Pharma	N/A	N/A	-$28.54M	-$0.69	-2.57
Cartesian Therapeutics	$38.91M	8.17	-$219.71M	-$52.83	-0.23

Do insiders & institutionals have more ownership in EPIX or RNAC?

75.1% of ESSA Pharma shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 15.5% of ESSA Pharma shares are owned by company insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cartesian Therapeutics beats ESSA Pharma on 10 of the 17 factors compared between the two stocks.